{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:08:39Z","timestamp":1790615319181,"version":"4.1.0"},"reference-count":25,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To report a case of agranulocytosis associated with initiation of famotidine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARY:<\/jats:title>\n                    <jats:p>An 87-year-old white man was admitted to the internal medicine department of an acute care hospital because of fever and agranulocytosis (granulocyte count 0). Eight days prior to admission, famotidine therapy had been initiated. Famotidine was discontinued and granulocyte\u2014macrophage colony stimulating factor was administered, with concomitant recovery of the granulocyte count and subsequent development of a leukemoid reaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>According to the Naranjo probability scale, famotidine was the probable cause of agranulocytosis. This is a rare adverse effect of this medication; only a few other cases have been reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Although agranulocytosis is a rare adverse effect of famotidine, the pharmacist and physician should be aware of this potentially fatal event. If any patient treated with famotidine develops fever, the clinician should consider, among other things, performing a white blood cell count.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1a045","type":"journal-article","created":{"date-parts":[[2003,6,4]],"date-time":"2003-06-04T16:20:34Z","timestamp":1054743634000},"page":"267-271","source":"Crossref","is-referenced-by-count":5,"title":["Agranulocytosis Associated with Initiation of Famotidine Therapy"],"prefix":"10.1177","volume":"36","author":[{"given":"Esther-Lee","family":"Marcus","sequence":"first","affiliation":[{"name":"Esther-Lee Marcus MD, Head, Acute Geriatric Department, Herzog Hospital, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Mark","family":"Clarfield","sequence":"additional","affiliation":[{"name":"A Mark Clarfield MD FRCPC, Chief, Academic Affairs, Herzog Hospital; Active Staff, Division of Geriatric Medicine, Sir Mortimer B Davis \u2014 Jewish General Hospital, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef","family":"Kleinman","sequence":"additional","affiliation":[{"name":"Yosef Kleinman MD, Chairman, Internal Medicine Division, Bikur Cholim Hospital, Jerusalem"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Bits","sequence":"additional","affiliation":[{"name":"Helena Bits MD, Nephrology Specialist, Nephrology Unit, Bikur Cholim Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Darmon","sequence":"additional","affiliation":[{"name":"David Darmon MD, Chief, Nephrology Unit, Bikur Cholim Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nael","family":"Da'as","sequence":"additional","affiliation":[{"name":"Nael Da'as MD, Attending Physician, Internal Medicine Division, Hematology Consultant, Bikur Cholim Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2002,2,1]]},"reference":[{"key":"bibr-bibr1-aph.1A045","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(96)80177-9"},{"key":"bibr-bibr2-aph.1A045","first-page":"271","volume":"7","author":"Berardi RR","year":"1988","journal-title":"Clin Pharm"},{"key":"bibr-bibr3-aph.1A045","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)09410-0"},{"key":"bibr-bibr4-aph.1A045","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr-bibr5-aph.1A045","doi-asserted-by":"publisher","DOI":"10.1007\/BF01738302"},{"key":"bibr-bibr6-aph.1A045","doi-asserted-by":"publisher","DOI":"10.1177\/106002809402800326"},{"key":"bibr-bibr7-aph.1A045","first-page":"430","volume":"3","author":"Aymard J-P","year":"1988","journal-title":"Med Toxicol Adverse Drug Exp"},{"key":"bibr-bibr8-aph.1A045","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856030-00002"},{"key":"bibr-bibr9-aph.1A045","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1995.tb00686.x"},{"key":"bibr-bibr10-aph.1A045","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1999.tb127696.x"},{"key":"bibr-bibr11-aph.1A045","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.2.523"},{"key":"bibr-bibr12-aph.1A045","first-page":"185","volume":"34","author":"Huber R","year":"1996","journal-title":"Int J Clin Pharmacol Ther"},{"key":"bibr-bibr13-aph.1A045","first-page":"256","volume":"8","author":"Byron JW","year":"1980","journal-title":"Exp Hematol"},{"key":"bibr-bibr14-aph.1A045","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-4-566"},{"key":"bibr-bibr15-aph.1A045","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.4.299.30941"},{"key":"bibr-bibr16-aph.1A045","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.1997.35749"},{"key":"bibr-bibr17-aph.1A045","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)80161-2"},{"key":"bibr-bibr18-aph.1A045","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb03048.x"},{"key":"bibr-bibr19-aph.1A045","first-page":"2031","volume":"8","author":"Spikkelman A","year":"1994","journal-title":"Leukemia"},{"key":"bibr-bibr20-aph.1A045","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08042.x"},{"key":"bibr-bibr21-aph.1A045","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1999.9.29"},{"key":"bibr-bibr22-aph.1A045","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19042"},{"key":"bibr-bibr23-aph.1A045","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.17.2186-JFD10004-3-1"},{"key":"bibr-bibr24-aph.1A045","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199324040-00005"},{"key":"bibr-bibr25-aph.1A045","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199121030-00003"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:05:59Z","timestamp":1777374359000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1A045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["10.1345\/aph.1A045"],"URL":"https:\/\/doi.org\/10.1345\/aph.1a045","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}